Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

BACKGROUND: Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30–65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Buzdar, Aman U, Suman, Vera J, Meric-Bernstam, Funda, Leitch, A Marilyn, Ellis, Matthew J, Boughey, Judy C, Unzeitig, Gary, Royce, Melanie, McCall, Linda M, Ewer, Michael S, Hunt, Kelly K
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4176878/
https://ncbi.nlm.nih.gov/pubmed/24239210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70502-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge